Adult cardioplegia heat exchanger MPS® 3

Overview
The Quest™ MPS® 3 (MPS® 3) Myocardial Protection System is a cardioplegia delivery platform that visually links cardioplegia administration and cardiac activity. Its coordinated drug delivery technology minimizes patient hemodilution associated with traditional cardioplegia and is designed to deliver precision microplegia with optimized flow distribution for reliable induction and sustained myocardial protection.

Key Capabilities

• Coordinated drug delivery to reduce hemodilution and support improved clinical outcomes
• Auto-Start feature to rapidly deliver an induction dose, facilitating quicker aortic valve closure and faster cardiac arrest
• Protocol flexibility: adjustable parameters in real time to support any ratio, strategy or methodology
• Real-time capture and recording of drug volumes and concentrations during procedures
• Active Monitoring Controller (AMC) providing concise, actionable information to the perfusionist
• Precision drug control with organized drug records to reduce medication errors and display exact concentrations in real time
• Safety features including instructional alerts/alarms on the AMC and an internal backup battery

ND (No Disinfection) Technology
The MPS® 3 ND system removes residual water from the cardioplegia circuit using dripless connectors, reducing the risk of Mycobacterium chimaera contamination associated with water-based heater‑cooler circuits. The ND variant is developed to limit internal water-circuit disinfection requirements (only exterior surfaces require routine disinfection).

ND Technology — Cost Considerations

• Average annual disinfection cost referenced: $7,000 per unit
• Average surgical site infection (SSI) cost/incident referenced: $28,219

Clinical & Economic Benefits
The MPS® 3 supports microplegia delivery that reduces hemodilution compared with traditional diluted cardioplegia. Reported clinical benefits of microplegia include improved myocardial protection, maintenance of an aerobic myocardial environment, reduced transfusion rates, decreased need for hemoconcentrators, and lower use of inotropes and blood products.

Evidence / Outcomes Highlights

• Reported ~5.25% reduction in adverse events in cited clinical study
• Reported reductions in length of stay and medication/hospital costs in referenced studies (examples provided in product literature)

Data Collection & Pharmacy Management
The MPS® 3 ND captures and stores procedural data including drug lists and dosages per case. Data export is possible via removable flash drive for analysis. The system enables precise drug tracking and allows drawing drugs directly from vials, eliminating the need to compound multi‑ingredient cardioplegia solutions and reducing pharmacy waste.

Heat Exchanger Delivery Sets
The MPS® 3 supports new 16‑core heat exchanger delivery sets that deliver cardioplegia at cooler temperatures more efficiently across flow rates and provide an additional access port for bolus delivery or sampling. A retrofit locking block conversion kit is available to allow older MPS® 2 consoles to accept both 10‑core and 16‑core heat exchangers (conversion kit catalog number referenced in product literature).

Resources Mentioned
Product literature referenced on the product page includes a product brochure, an MPS® 3 & 3 ND product catalog/guide, heat‑exchanger sell sheet/flyer, and an IFU for Myocardial Protection Systems. A product video demonstrating the MPS® 3 is also available.

Benefits Summary

• Enhanced control, accuracy, safety and flexibility for perfusionists and surgical teams
• Reduced hemodilution through precision microplegia delivery
• Real‑time analytics and adjustable parameters during procedures
• Potential cost savings via reduced disinfection needs (ND), lower transfusion and medication use, and decreased hospital resource utilization

Technical specifications

• Commercial name / model: MPS® 3 (Quest™ MPS® 3 System)
• ND variant available: MPS® 3 ND (No Disinfection technology)
• Auto‑Start functionality to initiate induction dose
• Active Monitoring Controller (AMC) with instructional safety alerts/alarms
• Real‑time capture and recording of drug volumes and concentrations
• Precision microplegia delivery: independent control of additive and arrest agents
• Supports 16‑core heat exchanger delivery sets; retrofit locking block conversion kit available for MPS® 2 (catalog number referenced)
• Internal backup battery for continued operation during power interruptions
• Data export via removable flash drive for case data and analytics
• Designed to draw drugs directly from vials (reducing the need for compounding)